MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA
Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in eczema patients. K201 was very well tolerated.K201 is a topical and steroid-free treatment of mild to moderate atopic eczema which is designed to alleviate itching and reduce dryness